2018

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.

Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R.

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.

Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R.

[Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.

Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.

Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C.

File name 

2017

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.

Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, Thomas F.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.

Ciccolini J, Barbolosi D, Meille C, Lombard A, Serdjebi C, Giacometti S, Padovani L, Pasquier E, André N.

A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients.

Becher F, Ciccolini J, Imbs DC, Marin C, Fournel C, Dupuis C, Fakhry N, Pourroy B, Ghettas A, Pruvost A, Junot C, Duffaud F, Lacarelle B, Salas S.

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.

Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D.

Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.

Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L.

Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.

Barbolosi D, Summer I, Meille C, Serre R, Kelly A, Zerdoud S, Bournaud C, Schvartz C, Toubeau M, Toubert ME, Keller I, Taïeb D.

Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

Bregigeon S, Solas C, Faucher O, Obry-Roguet V, Tamalet C, Poizot-Martin I.

Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.

Taton A, Colson P, Dhiver C, Ruiz JM, Bregigeon S, Tomei C, Ressiot E, Menard A, Poizot-Martin I, Ravaux I, Lacarelle B, Solas C.

Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe.

Menard A, Montagnac C, Solas C, Meddeb L, Dhiver C, Tomei C, Ravaux I, Tissot-Dupont H, Mokhtari S, Colson P, Stein A.

Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases.

Cloarec N, Solas C, Ladaique A, Tamalet C, Zaegel-Faucher O, Bregigeon S, Canet B, Cano CE, Poizot-Martin I.

Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole.

Bennis Y, Bodeau S, Lutun A, Gourmel A, Solas C, Quaranta S, Guillaume N, Chouaki T, Lemaire-Hurtel AS, Masmoudi K.

Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers.

Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O.

Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration.

Du Repaire T, Vigne P, Guedon A, Fanciullino R, Gauthier-Villano L, Peres PB, Pourroy B.

Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.

Le Grand M, Berges R, Pasquier E, Montero MP, Borge L, Carrier A, Vasseur S, Bourgarel V, Buric D, André N, Braguer D, Carré M.

2016

Prevention of fluoropyrimidine toxicity: do we still have to try our patient’s luck?

Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, van Kuilenburg ABP.

Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.

Gouri A, Dekaken A, El Bairi K, Aissaoui A, Laabed N, Chefrour M, Ciccolini J, Milano G, Benharkat S.

Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.

Serre R, Benzekry S, Padovani L, Meille C, André N, Ciccolini J, Barlesi F, Muracciole X, Barbolosi D.

Nucleoside analogs: ready to enter the era of precision medicine?

Ciccolini J, Serdjebi C, Le Thi Thu H, Lacarelle B, Milano G, Fanciullino R.

An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.

Padovani L, Baret A, Ciccolini J, Taieb D, Bardia F, Teissonnier L, Muracciole X, Barlesi F, Barbolosi D.

Monoclonal antibodies for treating gastric cancer: promises and pitfalls.

Sibertin-Blanc C, Ciccolini J, Norguet E, Lacarelle B, Dahan L, Seitz JF.

Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.

Venton G, Adam H, Colle J, Labiad Y, Mercier C, Ivanov V, Suchon P, Fanciullino R, Farnault L, Costello R.

First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever.

Menard A, Colson P, Catherine D, Isabelle R, Christelle T, Meddeb L, Ben Ali S, Solas C, Stein A.

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.

Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group.

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.

Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C

A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety.

Poizot-Martin I, Brégigeon S, Tamalet C, Bouabdallah R, Zaegel-Faucher O, Obry-Roguet V, Ivanova A, Cano CE, Solas C.

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).

Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC27 BOCEPREVIH Study Group.

2015

Computational oncology–mathematical modelling of drug regimens for precision medicine.

Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N.

Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.

Fanciullino R, Mercier C, Serdjebi C, Venton G, Colle J, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.

Launay M, Dahan L, Duval M, Rodallec A, Milano G, Duluc M, Lacarelle B, Ciccolini J, Seitz JF.

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N, Ciccolini J.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E, André T, Seitz JF, Montérymard C, Arsene D, Volet J, Abakar-Mahamat A, Lecomte T, Guerin-Meyer V, Legoux JL, Deplanque G, Guillet P, Ciccolini J, Lepage C, Dahan L.

Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.

Venton G, Colle J, Mercier C, Fanciullino R, Ciccolini J, Ivanov V, Suchon P, Sebahoun G, Beaufils N, Gabert J, Hadjaj D, Costello R.

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter.

Ciccolini J, Serdjebi C, Barbolosi D, Lacarelle B, Barlesi F.

Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L.

2014

Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters.

Fanciullino R, Mollard S, Correard F, Giacometti S, Serdjebi C, Iliadis A, Ciccolini J.

Trastuzumab-induced cardiotoxicity: is it a personalized risk?

Milano GA, Serres E, Ferrero JM, Ciccolini J.

Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice.

Hartung N, Mollard S, Barbolosi D, Benabdallah A, Chapuisat G, Henry G, Giacometti S, Iliadis A, Ciccolini J, Faivre C, Hubert F.

Metronomics chemotherapy: time for computational decision support.

Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B, André N, Barlesi F

Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?

Serdjebi C, Ciccolini J, Fina F, Delarue A, Verschuur A, Lacarelle B, Ouafik L, André N.

Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.

Peters GJ, Honeywell RJ, Maulandi M, Giovannetti E, Losekoot N, Etienne-Grimaldi MC, Milano G, Serdjebi C, Ciccolini J

Metronomics: towards personalized chemotherapy?

André N, Carré M, Pasquier E.

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.

Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F.

Phone: +33(0)491835509
Marseille 13005
Faculté de Pharmacie